Inventor · disambiguated record
Frank Delfino
Also filed as: DELFINO FRANK · DELFINO FRANK J
25 granted patents·9 pending applications·204 citations·filing 2014–2024
95Inventor score
Files withREGENERON PHARMA34
Top patents by PatentIndex Score
34 records- 0198US9302015B2Anti-PRLR antibodies and methods for killing PRLR-expressing cellsREGENERON PHARMA·Filed 2014·Granted Apr 5, 2016·82 cites·57 claims
- 0297US10772972B2Anti-STEAP2 antibody drug conjugates, and compositions and uses thereofREGENERON PHARMA·Filed 2017·Granted Sep 15, 2020·44 cites·41 claims
- 0394US11633501B2Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereofREGENERON PHARMA·Filed 2020·Granted Apr 25, 2023·3 cites·14 claims
- 0494US11414494B2Anti-GITR antibodies and uses thereofREGENERON PHARMA·Filed 2020·Granted Aug 16, 2022·3 cites·26 claims
- 0594US11384153B2Bispecific anti-BCMA x anti-CD3 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Jul 12, 2022·16 cites·24 claims
- 0693US9475875B2Anti-EGFRvIII antibodies and uses thereofREGENERON PHARMA·Filed 2015·Granted Oct 25, 2016·14 cites·9 claims
- 0791US11129903B2Multispecific antigen-binding molecules and uses thereofREGENERON PHARMA·Filed 2016·Granted Sep 28, 2021·8 cites·30 claims
- 0891US10738124B2Anti-EGFRvIII antibodies and uses thereofREGENERON PHARMA·Filed 2018·Granted Aug 11, 2020·3 cites·27 claims
- 0990US10806780B2Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereofREGENERON PHARMA·Filed 2018·Granted Oct 20, 2020·4 cites·17 claims
- 1090US10738126B2Anti-GITR antibodies and uses thereofREGENERON PHARMA·Filed 2017·Granted Aug 11, 2020·4 cites·4 claims
- 1187US11352446B2Methods of making multispecific antigen-binding moleculesREGENERON PHARMA·Filed 2017·Granted Jun 7, 2022·4 cites·26 claims
- 1287US11191844B2Multispecific antigen-binding molecules and uses thereofREGENERON PHARMA·Filed 2016·Granted Dec 7, 2021·4 cites·31 claims
- 1387US9545451B2Anti-PRLR antibodies and methods for killing PRLR-expressing cellsREGENERON PHARMA·Filed 2014·Granted Jan 17, 2017·6 cites·21 claims
- 1484US11958910B2Bispecific antigen binding molecules that bind HER2, and methods of use thereofREGENERON PHARMA·Filed 2021·Granted Apr 16, 2024·1 cites·22 claims
- 1584US11559576B2Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereofREGENERON PHARMA·Filed 2020·Granted Jan 24, 2023·1 cites·23 claims
- 1684US9688764B2Methods of treating breast cancer by administering anti-human prolactin receptor (PRLR) antibodiesREGENERON PHARMA·Filed 2016·Granted Jun 27, 2017·3 cites·47 claims
- 1783US2025064913A1Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1882US10683354B2Antibody-drug conjugates comprising anti-prolactin receptor (PRLR) antibodies and methods of use thereof to kill PRLR-expressing cellsREGENERON PHARMA·Filed 2018·Granted Jun 16, 2020·1 cites·26 claims
- 1982US10106616B2Antagonist antibodies to human prolactin receptor (PRLR)REGENERON PHARMA·Filed 2017·Granted Oct 23, 2018·2 cites·16 claims
- 2080US12115216B2Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereofREGENERON PHARMA·Filed 2022·Granted Oct 15, 2024·0 cites·19 claims
- 2175US12258412B2Nucleic acid molecules encoding bispecific anti-BCMA x anti-CD3 antibodiesREGENERON PHARMA·Filed 2022·Granted Mar 25, 2025·0 cites·20 claims
- 2275US10047160B2Anti-EGFRvIII antibodies and uses thereofREGENERON PHARMA·Filed 2016·Granted Aug 14, 2018·1 cites·13 claims
- 2374US2024190973A1Anti-fgfr2 antibodies and methods of use thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2473US12297257B2Multispecific antigen-binding molecules and uses thereofREGENERON PHARMA·Filed 2021·Granted May 13, 2025·0 cites·30 claims
- 2573US2023042324A1Anti-gitr antibodies and uses thereofREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2672US11866502B2Anti-FGFR2 antibodies and methods of use thereofREGENERON PHARMA·Filed 2021·Granted Jan 9, 2024·0 cites·65 claims
- 2772US11608380B2Anti-EGFRvIII antibodies and uses thereofREGENERON PHARMA·Filed 2020·Granted Mar 21, 2023·0 cites·11 claims
- 2871US2024325445A1Chimeric Antigen Receptors with BCMA Specificity and Uses ThereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2967US2022267477A1Methods of making multispecific antigen-binding moleculesREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3066US2025171516A1Peptide acids as a glp1r agonist and antibody-drug conjugates thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3165US12150959B2Chimeric antigen receptors with BCMA specificity and uses thereofREGENERON PHARMA·Filed 2019·Granted Nov 26, 2024·0 cites·25 claims
- 3264US2023330254A1Anti-glp1r antibody-tethered drug conjugates comprising glp1 peptidomimetics and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3360US2024293566A1ANTI-EGFRvIII ANTIBODY DRUG CONJUGATES AND USES THEREOFREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3456US2024226163A1Chimeric Antigen Receptors with MAGE-A4 Specificity and Uses ThereofREGENERON PHARMA·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Frank Delfino files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →